Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do http://www.frost.com/c/10024/home.do - Healthcare Research Frost & Sullivan Innovations in Drug Discovery and Development Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-18-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-18-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across new technologies enabling drug discovery and development. The service encompasses recent advances in nutrient sensing, microfluidic assays, controlled drug delivery, nanosensing, DNA library screening, biosimilars, and breakthrough treatment platforms. Additionally, this TOE summarizes technology trends and innovations related to virtual screening methods for drug discovery applications. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Nutrient sensing, microfluidics, epilepsy, silicon-based module, monitored drug delivery, nanosensors, DNA-encoded libraries, drug discovery breast cancer, Gorlin Syndrome, patidegib, topical therapy, hedgehog inhibitor, nevoid basal cell carcinoma, virtual screening Fri, 8 Dec 2017 00:00:00 +0000 Key Developments Driving the Biotech Industry http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-64-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-64-00-00 This edition of the Genetic Technology TOE depicts the life sciences trends across recent genetic technology and biopharma advances. Genetic technology, biopharmaceuticals development and regulatory approval, CRISPR/Cas9 gene editing technology, and CAR-T cell therapy are profiled in the TOE. The corresponding clinical trials scenario for genetically modified T-cell immunotherapy for the treatment of cancer is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biopharmaceuticals, CRISPR/Cas9 Editing, CAR-T Cell therapy, comprehensive genomic profiling, genetically modified T-cell immunotherapy, cancer treatment Fri, 8 Dec 2017 00:00:00 +0000 Technologies Enabling Improved Skincare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-63-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-63-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across skincare. Recombinant DNA technology, probiotic formulations, and phage proteins for enhanced skincare are profile in the TOE. The corresponding technology innovation scenario across skin microbiome and ageing is depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Skincare, recombinant DNA technology, phage proteins, DNA assays, probiotics, pathogenic skin bacteria Fri, 1 Dec 2017 00:00:00 +0000 Africa Healthcare Industry Outlook, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD35-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD35-01-00-00-00 In this research deliverable, Frost & Sullivan s analyst team provides bold perspectives and predictions for the African healthcare industry in 2017. The markets covered include pharmaceuticals and biotechnology, in-vitro diagnostics, medical devices, medical imaging and healthcare IT. The analysis captures the impact of trends that are expected to transpire over the upcoming year as organisations shift to prepare for the future. This study provides guidance on where to find the greatest opportunities for expansion. The continuous burden of disease on the continent and a dampened economic outlook will see the African healthcare industry focussing on more cost-effective products and services. In addition, the regulatory environment will see a major transformation in each country. Areas exhibiting high growth opportunities will be the main focus of governments and industries alike. Business models specific to the African continent will be pursued in contrast to those in the larger markets of developed nations. The growth trends of emerging markets such as China, India and Brazil will play a key role in shaping the healthcare outlook of the African market. Major investments in key health sectors will be seen in 2017, with an important focus on digital transformation. Some of the expected areas of focus are advanced diagnostic tools, artificial intelligence and mHealth. Mergers and acquisitions are expected as stakeholders collaborate to achieve common outcomes. The outlook foresees increased collaboration and M&A activities between the life sciences and medical device industries, in which product designs will support prevention of the onset of chronic and degenerative diseases. The focus on communicable diseases such as HIV/AIDS and malaria will continue to be in the spotlight in 2017 for a majority of the nations. Health spending is expected to rise in the continent with governments aiming to meet millennium development goals.--BEGIN PROMO--

Research Highlights

  • Market overview and projections for the African healthcare market in 2017
  • Revenue forecast by key African healthcare sector
  • Key predictions for the market in 2017 by segment
  • Key trends and growth opportunities affecting the African healthcare market
  • Strategic recommendations and future outlook of the African healthcare market

Key Issues Addressed

  • What are the top healthcare market predictions for 2017?
  • What will the market revenue and growth rate look like for the African healthcare industry?
  • What are the key projections and trends for major healthcare market segments?
  • What are the key technologies and trends to watch for in Africa during 2017?
  • What are the major growth opportunities to look out for?
Thu, 30 Nov 2017 00:00:00 +0000
Growth Opportunities in European Prenatal Genetic Testing Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD52-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD52-01-00-00-00 Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanced maternal age (over 35 years) and considerable popularity through social media and e-commerce channels. High level of merger and acquisition activity apart from numerous collaborations with regional clinical labs has supported the participants in marketing their products across the European region. Moreover, companies are also exploring new avenues to market their product by strategically tying up with IVF clinics, physicians, genetic counsellors and OBGYNs. Partnership with big data companies is anticipated to be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity, sensitivity, and cost of tests. The key business model emerging across the market is the collaboration of key participants with regional private clinical labs as well as public centres and organizations such as NHS to increase the market coverage in Europe.--BEGIN PROMO--


Research Scope

The key objectives of this growth insights study are to track the transformations in the prenatal genetic test market landscape in Europe for 2016-2021. The study aims at identifying growth opportunities across the market and suggesting most profitable business models to market players. Furthermore, the study provides an in-depth revenue and market analysis of 4 key segments within the prenatal landscape: NIPT, carrier screening for cystic fibrosis, invasive tests, and miscarriage tests. The study highlights industry challenges, growth drivers, restraints, competitive developments, key mergers and acquisitions (M&As), and investment opportunities. Key trends across the market with respect to physician and patient attitudes toward prenatal genetic screening and its probable impact on growth are analyzed. Additionally, top growth opportunities, profiles of game-changing companies, disruptive technologies and innovative business models, along with strategic recommendations are included.

Key Issues Addressed

  • Which are the most promising segments in the EU prenatal genetic testing market? Where is the most interest in terms of funding and innovation?
  • What are the most favorable business models across the prenatal testing market in Europe? How are companies coping with the market drawbacks and needs?
  • What are some of the most disruptive products in this market? Who are the key players in the market?
  • What are the gaps in the market that encourage penetration and provide opportunities to new entrants?
Thu, 30 Nov 2017 00:00:00 +0000
Future of Smart Hospitals http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1FF-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1FF-01-00-00-00 The entire industry has probably heard the term of Smart Hospitals or the Intelligent Hospitals . However, only a few truly understand the concept, as there is plenty of ambiguity around the term, with each stakeholder defining it in a way that relates to themselves and their services. Some even confuse a digital hospital to a smart hospital. However, an all-encompassing approach, which defines every element of the concept is lacking. Application of the concept is also a challenge very few hospitals have the financial resources to implement all the smart solutions necessary to become a smart hospital. However, there are strategies that can enable implementation of smart solutions in a piecemeal approach to become smart. Indeed, a majority of existing global hospitals already have or are likely to implement smart solutions. A few smart hospital projects do exist already and are spread across the globe. Additionally, a majority of the new hospital projects (brownfield and greenfield ventures) in the hotspot areas of Canada, Nordic regions, and Australia are likely to be full-scale smart hospital projects. Without a doubt, smart hospitals will have a major impact on global healthcare systems. Hospital expenditures account for the largest share of healthcare expenditures, and as global economies struggle to reduce overall expenditures on health, smart hospitals will prove to be an effective tool to achieve that target. Additionally, smart hospital approaches enable better quality of care with personalized approaches and reduced medical errors to achieve better patient outcomes. To cater to the trend of consumerization in healthcare, smart hospitals employ a patient-centric approach to ensure patient experience is optimal, allowing for better revenue generation. This study covers the market imperative for moving toward smart solutions and hospitals, the very definition of a smart hospital along with its framework, the difference between a digital hospital and a smart hospital, profiles of select smart hospitals across the world, and the three areas a smart hospital must cover, such as operational efficiency, clinical excellence, and patient centricity. Additionally, it offers key takeaways for the industries serving smart hospitals medical devices, pharmaceuticals and life sciences, health IT, internal logistics, and even facilities management and also provides select growth opportunities for vendors to capitalize on. It also highlights the challenges faced in achieving the smart hospital vision, while providing some strategic insight into how these could be alleviated. Wed, 29 Nov 2017 00:00:00 +0000 Diabetes and Mental Health - Anger, Burnout, Compulsive Eating, and Depression http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298056345 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298056345 World Diabetes Day (WDD) is celebrated annually on November 14 with the aim of increasing awareness of the effects of diabetes and the complications caused by the disease. The number of diabetics in the world stands at 415 million as of 2015. If the epidemic of Diabetes were a country Tue, 28 Nov 2017 00:00:00 +0000 Growth Opportunities in the Global Digital Pathology Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD55-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD55-01-00-00-00 Shortage of pathologists and the rise in new cancer cases are the key drivers for the adoption of digital pathology solutions globally. Digital pathology enhances the productivity of pathologists by 10% to 15%, thereby improving the overall efficiency of healthcare providers. Digital pathology solutions find the best fit in oncology care. According to WHO estimates, the number of new cases is expected to rise by about 70% over the next two decades. Digital pathology solutions are likely to be useful in cancer diagnosis, as these systems allow physicians to take and consider the second opinion on critical cases quickly. In addition, use of digital pathology in drug discovery enables pharmaceutical companies to remove bias and provide quantifiable results. The US research segment currently contributes to a significant part of the revenue, as digital pathology devices were not approved for primary diagnosis until Philips got the approval for Intellisite in April 2017. The approval is expected to increase the adoption of digital pathology in primary diagnosis, and further approvals of whole slide scanners are expected in the next 3 to 5 years, leading to an increase in competition. Despite higher efficiency and clinical effectiveness, the high cost of digital pathology solutions has been one of the key market growth restraints, especially in the small-to-mid-sized laboratory segment. However, this is expected to change in the future, driven by new business models and partnerships among vendors. Mon, 27 Nov 2017 00:00:00 +0000 Technologies Enabling Dendritic Cell Targeting for Autoimmune/Inflammatory Disease Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-62-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-62-00-00 This edition of the Genetic Technology TOE depicts trends across technologies that enable dendritic cell targeting for autoimmune/inflammatory disease therapy. Respiratory inflammation, myasthenia gravis, systemic lupus erytematosus, and other autoimmune disorders are profiled in the TOE. Recent patents related to dendritic cell targeting for autoimmune diseases have also been profiled. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Dendritic cell targeting, autoimmune diseases, inflammatory disorders, psoriatic inflammation, airway inflammation, immune tolerance, myasthenia gravis, plasmacytoid dendritic cells, systemic lupus erythematosus Fri, 24 Nov 2017 00:00:00 +0000 Global Precision Medicine IT Solutions for Oncology Companies to Action, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1E9-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1E9-01-00-00-00 Healthcare data analytics refers to information technology (IT) solutions and services that mine structured and unstructured digital content generated by healthcare industry stakeholders with the goal of achieving a predefined outcome. The healthcare industry is witnessing a redefinition of value through the changing expectations of care quality, reimbursement models, and patient experience. To deliver new forms of value, industry stakeholders need a far more granular dissection of data; payers, providers, and pharmaceutical and medical technology companies are taking this move very seriously. To support these rapidly changing stakeholders, data analytics vendors are bringing new and innovative solutions to the market that can help solve specific business issues around developing new solutions, revenue streams, operating models, and target customers. This report profiles vendors that are offering promising, disruptive, and pioneering solutions across diverse domains in precision medicine for oncology. It brings the most recent and successful and/or high-potential companies to light. The focus has been to identify vendors that bring in the advantage purely in terms of analytics not other components of data management and meaningful use. These companies create extraordinary value for their internal and external stakeholders by showcasing visionary leadership and implementing industry best practices, and through business model innovation. Precision medicine for oncology is defined as patient-specific cancer care that is aided by a targeted software suite. The realm of precision medicine is determined by providers willingness and ability to capture and normalize disparate patient data including clinical, socioeconomic, behavioral, and genomic to identify evidence-based treatments that are ideal for each patient. Key questions this study will answer: What are the current growth opportunities in precision medicine for oncology? What is the impact of the external industry environment on this market? Which unique companies are introducing new and innovative solutions? How do these companies intend to transform healthcare industry paradigms over the next 5 years? What are their action plans and potential for growth? What are the key success factors in the market? Fri, 24 Nov 2017 00:00:00 +0000 Innovation Profiles Featuring Spatial Frequency Domain Imaging, Algorithmic Scheduling, Cloud-based Medical Image Management, Ultrasound-on-a-chip Technology, Augmented Reality for 3D Modeling in Dentistry and Medical Training http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1A-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-1A-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles innovations in medical and diagnostic imaging. Some of the profiles covered include spatial frequency domain imaging, algorithmic scheduling, cloud-based medical image management, ultrasound-on-a-chip technology, augmented reality for 3D modeling in dentistry and medical training, artificial intelligence for breast tomosynthesis, and an intuitive cloud platform. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Spatial frequency domain imaging, algorithmic imaging, cloud-based medical image management, ultrasound-on-a-chip, augmented reality for 3D modeling in dentistry, augmented reality-based medical training, artificial intelligence for breast tomosynthesis, intuitive cloud platform Fri, 24 Nov 2017 00:00:00 +0000 Global Biologics Market Companies-to-Action http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD83-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD83-01-00-00-00 This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc., which provide technologically advanced solutions for conducting clinical trials to support complex drug manufacturing processes, thus creating integrated business models in addition to the above mentioned strategic analysis, a detailed biologic product pipeline, and a SWOT analysis of the key players has been undertaken. Some of the key questions answered by the study include: What are the current growth opportunities in biologics? What is the impact of the external environment on this market? Which are the leading companies that are introducing new and innovative products in the market? How do these companies intend to transform the industry paradigms in the next five years? What is their strategic focus and potential for growth? What are the key strategic imperatives in the biologics market? What are the key strategic collaborations/partnerships and investments made by the companies to stay on the growth trajectory? Mon, 20 Nov 2017 00:00:00 +0000 Innovations Supporting Medication Adherence, Robotic Surgery, Migraine Management, and Patient Engagement http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-17-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-17-00-00 The latest edition of Medical Device TOE profiles diverse innovations in the medical device industry. This issue covers novel innovations such as a tactile feedback-enabled surgical robot, a digital pill to track medication compliance, a hand-held device for treating ophthalmic conditions, and a smart bandage for wound care and technologies for patient engagement in hospitals. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Migraine, smart pills, robotic surgery, smart bandage, patient engagement Fri, 17 Nov 2017 00:00:00 +0000 Recent Advances in Technologies Directed against Dendritic Cells for Cancer Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-61-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-61-00-00 This edition of the Genetic Technology TOE profiles using dendritic cells for cancer management. The role of miRNA-128 in enhancing the anti-cancer functions of dendritic cells, lentiviral vectors that target dendritic cells, siRNA targeting dendritic cells, and dendritic cells targeting peptide are presented. The corresponding clinical trials scenario for dendritic cells targets is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Dendritic cell targets, cancer management, miRNA-128, siRNA, lentiviral vectors Fri, 17 Nov 2017 00:00:00 +0000 Technologies Empowering Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-17-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-17-00-00 This Drug Discovery TechVision Opportunity Engine (TOE) provides insights across new approaches fueling therapeutic advancements. The service encompasses a drug target discovery method, novel screening assays and innovative preclinical validation and testing platforms. Additionally, this TOE encompasses advances in treatment of pulmonary embolism, systemic sclerosis, as well as new drug repurposing methods and trends. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cell migration, invasion assay, drug target discovery, deubiquitylases screening, preclinical validation, preclinical testing, multi-organ chip, nanotechnology, pulmonary embolism, systemic sclerosis, cannabinoid, drug repositioning, phenotypic screening, drug repurposing, drug discovery Fri, 10 Nov 2017 00:00:00 +0000 Biopharma Advances Fueling Enhanced Disease Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-60-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-60-00-00 This edition of the Genetic Technology TOE depicts biopharmaceutical advances fueling enhanced disease management. Big pharma collaborations and ongoing clinical trials are depicted for therapies, including RNAi therapy. Industry influencers for further business development are included. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Disease management, gene therapy, cystinosis, tissue engineered blood vessel graft, RNAi therapy, Big Pharma collaboration Fri, 10 Nov 2017 00:00:00 +0000 Healthcare Cloud Computing Outlook, Global, 2016 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9AA-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9AA-01-00-00-00 The global market for healthcare cloud computing revenue generated by cloud computing services offered to providers will be worth just under $10 billion by 2021 primarily driven by the need for storage of the exponentially increasing volume of healthcare data. However, volume is only the beginning of the story; healthcare data in rapidly increasing in terms of complexity, sources, and applications all of which render the potential to develop new and innovative solutions that leverage cloud platforms. Current cloud applications among healthcare providers are dominated by non-clinical, back-office functions, especially those supporting information technology (IT) workflows. However, there is a definite peak in adoption of cloud-based clinical applications and in the next five years, key opportunities for cloud platforms will be storage, management, and analytics of imaging data; health information continuity through electronic medical records (EMRs), electronic health records (EHRs), and health information exchanges (HIEs); and telehealth solutions, especially teleradiology and virtual consultations. One major industry game-changer will be real-world data. The volume of unstructured medical and health data that is generated outside of clinical settings is growing exponentially while the need for such data sets is even direr among providers, pharmaceuticals, medical technology vendors, governments, and university researchers. Growing awareness of the benefits of open platforms and increasing industry focus on interoperability and collaborative solution design is creating a heavy demand for vertically integrated cloud platforms that open the data to multiple stakeholders who are willing to share the risks and the rewards of shared data assets. Technology vendors will introduce cloud-based digital ecosystems that enable sharing and better utilization of IT and human resources in the next five years. At the heart of these healthcare industry innovations are some fundamental shifts in the perception of cloud solutions globally. Cloud, which was once thought to be an unknown and uncertain IT environment, is now believed to be more secure than on-premise infrastructure and has proven to have better outcomes when it comes to data back-up and disaster recovery. Increasing confidence in cloud platforms, combined with the need to reduce cost, improve workflow speed and efficiency, and to leverage meaningful business intelligence is paving way for hybrid cloud adoption especially among developed markets. Thus, we see that there have been some extremely dramatic shifts in the way providers think of and use cloud platforms in the last few years, which will create opportunities for innovations in care delivery processes and models in the near future. Key questions this study will answer: How has the market for cloud solutions for healthcare providers changed in the last few years? What will be the growth opportunities in the next five years? Who are the current market participants? Are they well positioned to meet customer needs? How have customer expectations and buying behavior changed in the last few years? How will it evolve in the near future? What are the new business models in healthcare being introduced or facilitated by cloud technologies? What are some innovative, industry-specific solutions being introduced using cloud platforms? How do these impact current healthcare industry paradigms? How will care delivery ecosystems evolve using cloud technologies? Thu, 9 Nov 2017 00:00:00 +0000 Global Computed Tomography Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD3D-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD3D-01-00-00-00 The study aims to analyze and forecast the Computed Tomography market in North America (the United States and Canada), Europe and Asia-Pacific countries for 2016. Research Scope: Market trends (Utilization of conventional and emerging clinical applications, growth indicators, factors influencing ROI, critical unmet needs and potential game changing strategy, growth opportunities for computed tomography, emerging clinical application trends, technology trends driving CT growth, future prospects, product Profile, Competitive Structure; Market Metrics; Market Share; Revenues; Strategy) Regional Trends: North America (United States and Canada) Europe: Western Europe (Germany, United Kingdom, Italy, France, Spain, Benelux, Scandinavia); Eastern Europe (Poland, Czech Republic, Hungary, Bulgaria, Romania); Asia-Pacific (Australia, China, India, Japan, Thailand, Indonesia, Malaysia) Analysis by low end CT scanner (less than 16 slice), mid-low CT scanner (16-40 slice), mid-high CT scanner-64 slice and high end CT scanner(128, 256, and above, dual source and spectral imaging) and by the three regions. Market Measurements are analyzed for the year 2014-2016 and forecast up to 2021 Revenue and Year-on-Year growth rate by regions and segments. Pricing range and growth trend by sub-segment for the base year is discussed. An extensive list of manufacturers in CT space to watch out for in 2016 is provided. Computed Tomography (CT) has become ubiquitous in most secondary and tertiary care hospitals and diagnostic imaging centers as a standard diagnostic and screening tool for various body applications. Despite a matured segment, technological innovation in the recent years has resulted in system upgrading that has introduced various clinical applications focusing on pediatric, advanced cardiac applications, colon and lung cancer screening . With the advent of private hospitals and favorable reimbursements health insurance, there is more demand for patient safety and quality of technologies, reduced hospitalization and reduction in overall healthcare costs. Despite maturity, CT presents scope for replacement, especially in globally as most countries have 20% of the equipment aged over 10 years. Globally, countries are giving emphasis to safety and outcomes caused by X-ray systems, reduced radiation, seamless workflow, and automation. Business models focusing on managed services, pay per use and sharing services are changing the landscape of the CT procurement due to higher equipment cost. These factors determine the growth of the CT market. Strategies, growth analysis, competitive landscape, and future focus are discussed for vendor s (GE Healthcare, Philips Healthcare, Siemens Healthcare, Hitachi Medical, Samsung Neurologica and Neusoft Medical Systems). The base year for the study is 2016, with historic years 2014 and 2015 and 2017 to 2021 as forecast period. Mon, 6 Nov 2017 00:00:00 +0000 Technologies Fueling Biopharma and Life Sciences Research http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5F-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5F-00-00 This edition of the Genetic Technology TOE depicts life sciences trends across the biopharmaceutical industry. Different genetic technologies, antibody drug conjugates, mitochondrial based therapies are illustrated. The corresponding clinical trials scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Gene therapy, high-grade glioma, Risankizumab, antibody drug conjugate, mitochondrial network, healthy aging Fri, 3 Nov 2017 00:00:00 +0000 Assessment of the US Revenue Cycle Management Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1C3-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1C3-01-00-00-00 Revenue cycle management (RCM) refers to myriad administrative and clinical functions around the capture, management, and collection of patient service revenue. The RCM process starts with admission (patient access) and continues through to accounts receivable (payment and collections). A variety of RCM solutions (e.g., IT applications and services) are deployed to help healthcare providers perform different functions. The objective of this research service is to present a comprehensive analysis of the US RCM market with respect to trends, revenue growth potential, and the dynamics at play for RCM information technology (IT) and services deployed by hospitals and physician practices through 2022. Additionally, the report will analyze market forces impacting adoption of RCM IT and service solutions among hospitals and physician practices evaluate existing and emerging regulatory objectives centered on providers financial risk management initiatives highlight best practices in the areas of design and deployment of an integrated financial workflow that supports value-based care assess the outlook of outsourced or shared service-based RCM operating models identify 5 major growth opportunity areas related to RCM estimate the revenue potential of the total US RCM market (software applications and services), and include breakdowns by hospitals and physician practices, from 2016 to 2022 shortlist vendors that propose best-in-class solutions for hospitals and tphysician practices This study is segmented into major functional segments of RCM, Patient access Registration and charge capture Billing and collection In terms of end-user adoption, this study classifies the buyer market in two broad provider categories: Hospitals Physician practices The market projection ($ value) is stratified based on the following overarching RCM product segments: IT (software applications) Services Market Background The shift in population demographics coupled with the rise of risk or value-based reimbursement models is driving the need for better prediction and management of revenue cycles, especially for high and at-risk patient populations. The prevalence of legacy RCM IT systems, which do not optimally support the goal of building a broader but coordinated and enterprise-wide financial ecosystem, is restricting providers from achieving the desired results around healthcare cost and collection. Most US-based providers still grapple with low operating margins, resulting from poor accounts receivable (A/R) performance and high average denial volumes. Many health systems attribute this inefficiency to their suboptimal knowledge and implementation of value-based RCM pathways that require significant investments in RCM IT. The need for efficient claims processing, which in turn results in optimized collection of risk-based revenue, supports adoption of value-based financial management solutions. Most providers that embrace alternative payment models acknowledge the need to deploy progressive scheduling, billing, and analytics technology modules capable of digitizing the entire RCM ecosystem. This view results from the growing adoption of payer contracts with specific provisions for efficient claims management, in addition to the need for integrating new capabilities that will meet the increasing financial responsibility of patients with coinsurance and large deductibles. Overall, the top unmet market needs driving adoption of next-generation RCM solutions among health systems in US are: Comprehensive regulatory compliance and financial risk mitigation The ability to collaborate with payers to customize revenue cycle workflows Elimination of preventable operational expenses, attributed to claims processing Automated identification of hidden patterns and root causes of claim denial Optimized collection of payments, rebates, and incentives for patient services Real-time reporting of financial and operational performance at an enterprise level As a result, new growth opportunities involving external RCM solutions have gained precedence among many hospitals and physician practices. Most of them are willing to invest in advanced RCM capabilities that can streamline financial performance cost effectively by paving the way for seamless payer-provider communications pertaining to financial risk management. These end users are likely to prioritize procurement of RCM solutions from external IT vendors based on implementation evidence and cost/benefit benchmarks. Hence, going forward, they are expected to rely on RCM vendors with proven expertise in optimizing financial performance through comprehensive patient access, error-free claims preparation, automated billing workflows, and robust RCM analytics. Vendors with solutions that can complement providers incumbent value-based payment arrangements and RCM IT ecosystems are expected to thrive in this market. Tue, 31 Oct 2017 00:00:00 +0000 Growth Insights on the Global CRISPR/Cas9 Tools Market, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K242-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K242-01-00-00-00 Since its inception, CRISPR has gained strong traction from the global research community because of its huge potential in diverse applications. Considering CRISPR s disruptive and game-changing applications, a number of large and small participants have invested in this domain. Along the same line, CRISPR has witnessed a multi-fold uptake in funding from the National Institutes of Health (NIH) and other government agencies. As a result, these investments have led to significant growth in new product and application development, thereby creating new market segments and revenue growth opportunities for existing companies and new entrants. In 2017, the CRISPR/Cas9 tools market opportunity will likely be about $1.8 to $2 billion. The therapeutics and agriculture segments will contribute the most revenue potential. The market is currently highly fragmented, with a handful of global participants and a large number of application-focused participants operating in their respective segments. Competition in the therapeutics and agriculture domains is highly concentrated, and most market and technology developments have been focused around a few companies. Even large pharmaceutical companies have partnered with these existing participants to source innovation and to support their product development using CRISPR. With the ongoing patent war between the University of California and Broad Institute, this situation will likely remain the same. Frost & Sullivan expects that large pharmaceutical companies will only commit direct investments in this segment after understanding the final outcome of the ongoing patent cases. The objective of this research study is to consider and analyze all these market developments and present a realistic market landscape. This research publication covers insights on existing and emerging growth opportunities in the CRISPR/Cas9 tools market. The study covers qualitative market insights on various market segments and sub-segments, including agriculture, human therapeutics, research tools, and drug discovery activities. The report identifies existing gaps in product and service offerings of key participants across segments, disruptive technologies, and key market and technology trends. The research study further delves into the market s competitive landscape and patent licensing landscape analysis. Key Questions This Study Will Answer: Who are the key competitors in the emerging CRISPR/Cas9 market, both tools and therapeutics? What are the growth opportunities that companies should pursue now and in the future? To stay relevant, what are the competitive differentiators that companies should employ in an increasingly crowded competitive base? What is the current patent landscape for this domain, and what are the key associated opportunities? What are the key game-changing disruptive technologies that might impact future market development? Tue, 31 Oct 2017 00:00:00 +0000 Global Digital Pathology Market, 2017 Companies-To-Action http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD84-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD84-01-00-00-00 It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discovery, and companion diagnostics. Digital pathology can improve efficiency of pathologists by 10 15%, thereby helping the healthcare providers in filling such gaps. This factor is a key driver for the rapid growth in adoption of digital pathology solutions globally. In April 2017, FDA approved the IntelliSite Pathology Solution from Royal Philips. This was the first digital pathology product for which any US manufacturer received approval for primary diagnostics purpose. An expected increase in regulatory approval for digital pathology systems for primary diagnostics will support the growth in demand for these systems. To cater to the growing demand for digital pathology solutions, the industry has observed numerous partnerships, collaborations, and M&As. These strategies have been undertaken to expand product portfolio and deepen solution expertise while catering to changing customer demands. Research Scope: The key objectives of the companies-to-action for digital pathology study are to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. Further, the study provides an analysis of companies segregated by hardware, software, services and storage. It covers business profile, key solution offerings, target customer segments, service differentiators, and future growth strategies. The study also highlights growth opportunities, case study of notable market developments, key trends, mergers and acquisitions, for investment and collaboration opportunities. Companies mentioned in the study are Agfa Healthcare, Corista, Definiens, Fimmic Oy, GE (Omnyx), Hamamatsu, Huron Digital Pathology, Indica Labs, Inspirata, Leica Biosystems, OptraSCAN, Pathcore, Philips, Proscia, Sectra, Sunquest, Visiopharm, Ventana Medical Systems, Roche, and 3D Histech. Key questions this study will answer: How are digital pathology companies creating extraordinary value for stakeholders? Which are some unique companies that are introducing new and innovative solutions in the market? How do these companies intend to transform healthcare industry paradigms in the future? What is the impact of the external industry environment on this market? What is their action plan and potential for growth? What are the current growth opportunities in digital pathology? What are some key success factors in the digital pathology market? Which are the companies with whom partnerships can be forged? Tue, 31 Oct 2017 00:00:00 +0000 Transformation of the United States Medical Imaging Industry, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1FC-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1FC-01-00-00-00 The US medical imaging industry is undergoing a transformation with stakeholders across the ecosystem emphasizing collaborative population health-based approaches over conventional episode-based models of care delivery. Current reimbursement and regulatory factors are pushing the imaging industry away from a get bigger approach that emphasizes more imaging scans and towards a get better approach that emphasizes cost reductions and improved efficiency across the value chain. To this end, the imaging industry seeks to become more patient-centric, prioritizing improved patient experience and empowerment. To succeed in this transition, the imaging industry is moving beyond the modality and focusing on enhancing the value of the image itself. The industry seeks to create a coherent strategy to standardize the imaging process and integrate imaging into care protocols across multiple clinical areas. Introducing standardization into a fragmented care delivery landscape hinges on frictionless interoperability and sharing of data, which are widely regarded as the single-most important goal for the imaging industry. The ability to share and collate millions of imaging scans enables the industry to apply deep learning analytics solutions that will evolve best practices, enhance automation, and improve the workflow productivity of care provision. Questions the Study Will Answer: How are financial and regulatory policies impacting the medical industry? What are the current challenges being faced by regulators, radiologists, care providers, and payers in the imaging industry? What collaborative, multidisciplinary approaches are currently being adopted to overcome these challenges? What are the critical elements required for the industry to shift from reactive approaches towards imaging and become future ready? What are the new and evolving vendor-customer business models that consider care provider goals and budgets? What are the growth opportunities for care providers and radiologists? What are the growth opportunities for medical imaging OEMs? Where will the future medical imaging industry look like and what do stakeholders in the imaging ecosystem need to do to bring about this evolution? How are new technologies and solutions enabling the radiologist to play a direct more active role in improving patient outcomes? This research services also explores the next big trends in medical imaging that will contribute to the successful transformation of this industry. Trends include artificial intelligence, shift to population health management, the rise of teleradiology, and imaging workflow and process automation. This study also takes a look at the advantages offered by a select group of medical imaging market participants , namely Philips Healthcare, GE Healthcare, Siemens Healthineers, Canon/Toshiba, Ambra Health, Intelerad, and IBM Watson Health. Mon, 30 Oct 2017 00:00:00 +0000 Enhancing Molecular Insights for Improved Disease Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5E-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5E-00-00 This edition of the Genetic Technology TOE profiles about enhancing molecular insights for improved disease management. The TOE covers advanced genomic insights across pediatric healthcare, novel chimeric antigen receptor T cell (CAR-T) therapies garnering regulatory approval, new targets for Parkinson s disease, and partnerships for the development of mRNA cancer vaccines. The corresponding clinical trials scenario for Axicabtagene Ciloleucel is depicted, along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Enhanced molecular insights, improved disease management, genomic insights, pediatric healthcare, Chimeric Antigen Receptor T Cell (CAR-T) therapy, regulatory approval, Parkinson s disease, mRNA cancer vaccine. Fri, 27 Oct 2017 00:00:00 +0100 Growth Opportunities in the Global Cloud-Based Medical Imaging Informatics Market http://www.frost.com/prod/servlet/sublib/display-report.do?id=K135-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K135-01-00-00-00 As the cloud-based information technology (IT) model advances slowly in healthcare, following years of lasting apprehension and skepticism, it is pursuing its two-decades-long journey in the medical imaging field. Indeed, since the early 2000s, cloud-based solutions have provided a viable alternative to tape- and truck-based solutions for the long-term archival of medical image studies. Since then, cloud-based solutions have continued to develop into more advanced use cases, despite the challenging nature of medical image data in terms of file sizes and user expectations. The conventional on-premises model, whereby every enterprise has to buy, operate and maintain its own IT solutions is proving to be unsustainable in the era of big data, short-sighted given the pace of IT innovations, irrelevant under the interoperability imperative, and not the wisest economic choice. However, transitioning to a cloud-based imaging IT model is not an easy shift, whether for healthcare providers or for vendors who have to align with the new purchasing, business, management and governance models that this shift entails. This explains the widely varying levels of excitement and proactiveness with the cloud among vendors and providers. Cloud-based medical imaging informatics, as a subset of the total medical imaging informatics market, is segmented by its key 4 applications, namely: - Cloud-based image archiving, which has been advancing beyond deep archival to higher levels of accessibility - Cloud-based image distribution (inter- and cross-enterprise image exchange, image-enabled electronic health records (EHRs), patient portals and healthcare information exchanges (HIEs)) - Cloud-based image diagnosis (RIS, PACS, Teleradiology, Reporting), which can completely replace core on-premises RIS/PACS solutions - Cloud-based imaging analytics, with various types of applications across the clinical, operational and financial domains, which can be delivered on-demand as software-as-a-service as part of a cloud-based ecosystem or marketplace The study scope is global, and covers revenue and adoption projections including highlights of major developments across key geographies, along with a detailed assessment of 15 top growth opportunities for the market, namely: Risk Mitigation through Business Associate Agreements Capitalizing on a Given Region or Country Multi-Ology Imaging Alignment for Integrated Care Models Efficiency in Emergency Patient Management Dematerialized Image Sharing / CD Replacement Virtualized, Seamless Cloud Medical Image Exchange Diversification of Image Distribution Use Cases Cloud-Enabled Intra-Enterprise Image Liquidity Patient Engagement and Imaging Record Ownership Operating an Online Marketplace Cloud Platform Advanced SaaS Apps Delivered in Third-Party Platforms Deep/Machine Learning for Cognitive Cloud Computing Medical Imaging Clouds for Clinical Research Image-Enabling Healthcare Information Exchanges Participation in Industry Interoperability Initiatives Fri, 27 Oct 2017 00:00:00 +0100 Innovations in Whole Body Functional Imaging, Improved Patient Comfort During Mammography, Artificial Intelligence in Imaging Analytics, and 3D Medical Image Visualization http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-19-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-19-00-00 The latest issue of Medical and Diagnostic Imaging Technologies TOE profiles innovations in medical and diagnostic imaging. Some of the profiles covered include whole body functional imaging, improved patient comfort during mammography, artificial intelligence cardiovascular imaging, a ultra-wide fundus camera for improved macular disease diagnosis, and a 3D organ visualization system. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Whole body functional imaging, patient-assisted mammography, artificial intelligence-powered imaging, ultra-wide fundus camera, advanced analytics, mobile-based diagnostic solution, 3D organ visualization Fri, 27 Oct 2017 00:00:00 +0100 Growth Opportunity Assessment of Healthcare IT Market in Spain, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD76-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD76-01-00-00-00 UK, Germany, France and Spain collectively spend more than $6 billion on healthcare information technology (healthcare IT) while regional adoption stands at almost 80%. Healthcare IT markets in these countries are ready to embark upon the next level of digitalization where providers move from data-capturing solutions to those that can derive value from data through improving information sharing, analytics and clinical decision support. Spain is leading EMR market growth amongst EU countries, with approximately 90% of healthcare providers having an EMR, 85% of which are engaged in full capture of data. However, less than 15% of hospitals in the country share data outside their network. Majority of the data shared are patient records being shared within the hospital network or with the Ministry of Health. An administrative structure comprising autonomous communities and sites has led to variations in health system regulations, workflows and healthcare IT adoption. Primary care, on the other hand, has experienced a more uniform healthcare IT adoption with almost 95% of providers using digital systems. The 180 million investment under the Digital Agenda will help enhance the state of interoperability across the country, especially amongst ePrescription systems. Between December 2016 and March 2017, Frost & Sullivan conducted a survey of IT managers from 198 hospitals across Western European countries. Findings of the survey were further investigated through in-depth discussions with market vendors and Frost & Sullivan industry thought leaders. Outcomes of the research have been collated into a 4-part series detailing the HCIT landscape across EU4 (The United Kingdom, Germany, France and Spain). Our research found that in spite of a high level of EMR adoption only a little more than 15% of large hospitals share data beyond their organization. This has been a huge detriment to efficient and productive health data utilization across all countries included in this study. However, with changing care paradigms, such as focus on patient-centricity, innovation in care delivery models and the demand for workflow efficiency, improving health data continuity will be a key goal for both governments and providers over the next five years. As a result, interoperability, and standards development and adoption will be major priorities across health systems. Spain has traditionally been an import market for health technology and medical equipment. Leading market participants include Indra, Cerner and DXC Technology while IBM and Orion Health have a comparatively smaller presence than the three market leaders. Our survey results indicate that future market growth will come from system upgrades rather than investment in new systems or vendors. To promote local digital health vendors the government is initiating start-up incubators and innovation hubs. Several regions in Spain are becoming digital health innovation hubs and this can be validated by the high share of locally developed healthcare IT solutions in the market. For example, Catalonia s 734 healthcare-related companies attracted over EUR100 million in investment since 2013 and collaborations between start-ups and hospitals are also common. These start-ups will need to demonstrate a high degree of solution differentiation as they are currently playing more like small fish in a big pond. Chronic disease management and remote monitoring have been identified as strategic directions for health system reform by the government and a number of programs have been launched to support these care delivery models, such as, the strategy for chronic care, policy programme by the regional Ministry of Health and introduction of Complex Care Plan with public-private partnership. There have been several pilot programmes in innovative care models integrating health and social services, such as BSA-Badalona and Catalonia and Etxean Ondo from Basque Country. However, lack of business model scalability is a major impediment to large-scale adoption. eHealth solutions that facilitate self-management and integration of care will be in demand. This is only a sample of insights that you can gain through our research. Key questions answered in this study include: What are the current trends, challenges and drivers for healthcare IT investment? What will be the most promising growth opportunities and key investment areas over the next five years? How is health IT adoption evolving? What will be the impact and adoption of new technologies? How will these change current industry paradigms and/ or bring in new business models? How are the initiatives at national and regional level for eHealth adoption impacting the market? What is the current vendor landscape, tiers of competition in select segments (e.g., Total Health IT, EHR, PCIS)? How are they expected to evolve over the next five years? What do healthcare providers expect when investing in healthcare IT and how has this evolved over the years? What are the key vendor-/solution-selection criteria of providers while investing in health IT? Tue, 24 Oct 2017 00:00:00 +0100 Advancements in Magnets, Building Automation, Water Treatment, and Drug Delivery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-5D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-5D-00-00 This edition of the Inside R&D TOE features trends in a series of developments associated with innovations in targeted drug delivery, building automation and control, and permanent magnets. The TOE also focuses on developments and innovations in water and waste water treatments. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Magnets, building automation, single shot vaccines, hydrogen peroxide, coagulants Fri, 20 Oct 2017 00:00:00 +0100 Innovations Supporting Medication Adherence, Hospital Staffing, Ambulatory Diagnostic Devices, and Therapies for Cardiovascular Diseases http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-16-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-16-00-00 The latest edition of Medical Device TOE profiles diverse innovations in the medical device industry. This issue captures innovations such as a novel ultrasound-emitting balloon catheter for the treatment of peripheral artery diseases, digital stethoscope and portable optical imaging scanner for ambulatory use, and neuromodulation devices for the management of epilepsy and other peripheral nerve conditions. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Digital health, neuromodulation, lithotripsy, transcutaneous electrical nerve stimulation, medication adherence Fri, 20 Oct 2017 00:00:00 +0100 Recent Developments in Genomic and Proteomic Platforms http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-5D-00-00 This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across genomics and proteomics. Different advances in omics technologies, especially genomics and proteomics are depicted. Particular cases including cancer disease and inherited retinal disease are illustrated. The corresponding clinical trials scenario for inherited diseases is highlighted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genomics, proteomics, gene therapy, inherited retinal disease, liquid biopsy, protein engineering, inherited diseases Fri, 20 Oct 2017 00:00:00 +0100